Somewhere in the world, right now, a patient is taking a paracetamol tablet, a metformin pill, or an ibuprofen capsule manufactured by Granules India. Founded in Hyderabad in 1991, this $648 million company has built one of the pharmaceutical industry’s most vertically integrated manufacturing operations — controlling every step from active pharmaceutical ingredient synthesis through pharmaceutical formulation intermediates to finished dosage forms. It is a business built on the premise that the world’s most-consumed molecules deserve the world’s most efficient production.
Granules India’s competitive moat is not a patent portfolio or a niche therapy area. It is the manufacturing process itself. The company operates across the entire pharmaceutical value chain: synthesising active pharmaceutical ingredients (APIs), converting them into pharmaceutical formulation intermediates (PFIs), and pressing, coating, and packaging finished dosage forms (FDs). In FY 2025, finished dosages contributed 65% of standalone revenue, APIs accounted for 20%, and PFIs made up the remaining 15%.
This vertical integration is not common. Most generic pharmaceutical companies either manufacture APIs or produce finished dosages — few do both at scale. Granules does both, and does it for the highest-volume molecules in global healthcare: paracetamol (acetaminophen), metformin, ibuprofen, guaifenesin, and methocarbamol. These are not exotic speciality drugs. They are the backbone of primary care, consumed by billions of patients annually. Granules’ thesis is that manufacturing these molecules with superior cost efficiency, at massive scale, with consistent quality, is a genuinely defensible business.
The numbers bear this out. Revenue grew from $390 million in FY 2021 to $648 million in FY 2025, a compound annual growth rate of approximately 13.5%. The growth came not from dramatic product launches or geographic pivots, but from relentless operational improvement: better yields, tighter processes, and incremental capacity expansion across existing molecules.
Granules India is an overwhelmingly export-oriented company. Approximately 95% of revenue comes from international sales, with North America alone accounting for 66% and Europe contributing 19%. The remaining revenue comes from the rest of the world and a small domestic component. This is a company that manufactures in India but sells almost entirely to the most demanding regulatory markets on earth.
That regulatory exposure is both a strength and a requirement. Granules operates ten manufacturing facilities — seven in India, two in the United States, and one in Switzerland. Multiple facilities carry US FDA registration. In FY 2025, the company filed seven abbreviated new drug applications with the US FDA, nine marketing authorisation applications in Europe, and one over-the-counter application in Canada, bringing cumulative US FDA approvals to 71 ANDAs.
The two US manufacturing sites — in Virginia — give Granules something that most Indian pharma companies lack: local production capability in its largest market. This reduces supply-chain risk, shortens lead times, and provides a buffer against the logistics disruptions that periodically affect transcontinental pharmaceutical supply chains.
The pharmaceutical industry rewards scale in ways that few other industries match. A company that manufactures 10 billion paracetamol tablets per year has a fundamentally different cost structure from one that manufactures 100 million. Granules understood this from its founding. Dr. Krishna Prasad Chigurupati established the company in 1991 as a merchant exporter of bulk drugs, but the vision was always industrial: build the largest, most efficient production capacity for the world’s essential molecules.
That vision evolved through phases. In 1993, Granules established its first PFI facility at Jeedimetla and began exporting to the United States, Germany, and Australia. The company went public on the Hyderabad Stock Exchange in 1995. Each subsequent decade brought capacity additions, new molecule launches, and geographic expansion — always in service of the same core idea: volume, efficiency, integration.
Today, Granules’ manufacturing infrastructure spans API synthesis, granulation, compression, coating, and packaging. The company can take a raw chemical intermediate and deliver a finished, bottle-packaged tablet ready for pharmacy shelves, all within its own facility network. For customers — primarily large retail pharmacy chains and distributors in North America and Europe — this integration translates to supply security, competitive pricing, and consistent quality.
Granules’ revenue architecture reflects its integrated model. Finished dosages are the largest segment at 65% of standalone revenue, reflecting the company’s strategy of moving up the value chain from bulk APIs to higher-margin finished products. The API business at 20% serves both internal consumption and external sales to other formulation companies. PFIs at 15% represent the intermediate stage — granules, pellets, and blends that are sold to other manufacturers or converted internally into finished products.
Granules operates ten manufacturing facilities across three countries. Seven plants are located in India — primarily in Telangana and Andhra Pradesh — serving as the company’s production backbone for APIs, PFIs, and finished dosages. Two facilities in Virginia, United States, provide local manufacturing capability for the North American market. One facility in Switzerland supports European operations. Multiple facilities carry US FDA registration, and the company’s cumulative ANDA approval count reached 71 by FY 2025.
Sources: Granules India Limited Annual Reports FY2020–21 through FY2024–25. Granules India Q4 FY25 Earnings Presentation. US FDA facility registration data and ANDA approval records. Indian patent office records.